As of Oct 8, 2026 close
- Market cap
- $1.79B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $11.00$22.67
- Volume (live)
- -
- Avg. volume (3M)
- 1.28M
Generate Biomedicines (GENB) Stock Price & Financial Analysis
Generate Biomedicines Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $13.08 - $14.14 |
|---|---|
| 52-Week High | $22.67 |
| 52-Week Low | $11.00 |
| Open | $13.50 |
| Volume (last close) | 1.16M |
| Average Volume (3M) | 1.28M |
| Market Cap | 1.79B |
|---|---|
| Shares Outstanding | 128.24M |
| Price to Sales (P/S) | 55.23 |
| Price to Book (P/B) | 3.93 |
| EV/EBITDA | -7.67 |
| Revenue (TTM) | 32.49M |
|---|---|
| Net Income (TTM) | -234.41M |
| Free Cash Flow (TTM) | -245.88M |
| EPS (TTM) | $-2.39 |
| Profit Margin | -721.56% |
| Operating Margin | -751.19% |
| Return on Equity (ROE) | -51.40% |
| Debt to Equity | 0.14 |
| 50-Day MA | $15.51 |
|---|
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Generate Biomedicines at a Glance
Generate Biomedicines (GENB) has a market capitalization of $1.79B. The stock trades at 55.2× sales. Over the trailing twelve months it lost $234.41M on revenue of $32.49M and burned $245.88M of free cash flow. Revenue grew 55.9% year over year.
It holds $135.36M in cash and securities against $62.63M of debt, a net cash position of $72.73M.
Generate Biomedicines does not currently pay a dividend.
At $13.99 it sits within its 52-week range of $11.00 to $22.67.
Based on 4 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $26.00, 85.8% above the latest close.
Frequently Asked Questions About Generate Biomedicines
What is the current stock price for GENB?
As of the Oct 8, 2026 close, GENB stock trades at $13.99. The 52-week range is $11.00–$22.67, with a day range of $13.08–$14.14.
What is the P/E ratio for GENB?
The P/E ratio (Price-to-Earnings) for GENB is shown in the Key Statistics section. This valuation metric helps compare Generate Biomedicines, Inc. to industry peers.
Does GENB pay dividends?
Generate Biomedicines does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.
What do analysts recommend for GENB?
Based on 4 analysts, the consensus for GENB is Buy.
What is the market cap of GENB?
Generate Biomedicines's market capitalization is $1.79B, classifying it as a small-cap company. Generate Biomedicines operates in the Healthcare sector within the Biotechnology industry.